Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT06250738 Recruiting - Clinical trials for Psychological Distress

Shift-and-persist and Cardiometabolic Markers Among Women in Puerto Rico

Start date: February 17, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the feasibility and acceptability of a 4-week mindfulness program among young women in Puerto Rico with elevated stress. The main questions it aims to answer are: - how feasible and acceptable is a s a 4-week mindfulness program among participants with elevated stress - what are the changes in psychological resilience, psychological distress, health behaviors, and cardiometabolic markers Participants will be asked to - attend 4 weekly virtual sessions and daily mindfulness exercises at home - complete online study questionnaires

NCT ID: NCT06240273 Not yet recruiting - Metabolic Syndrome Clinical Trials

Assessment of Therapeutic Potential of Stigma Maydis (Cornsilk) on Metabolic Syndrome

cornsilk
Start date: February 20, 2024
Phase: N/A
Study type: Interventional

Over the past two decades, there has been an increase in the number of people with nutrition related maladies due to changes in their dietary habits and lifestyle. Cardiovascular disease, type 2 diabetes, metabolic syndrome, obesity, and cancer have emerged as prominent contributors to both illness and death, particularly as the population continues to age. The mortality figures for cardiovascular disease and diabetes varied between 179.8 to 765.2 per 100,000 individuals, with the most elevated rates observed in poor nations. The occurrence of metabolic syndrome was markedly prevalent, spanning from 19% to 45%. The incidence of overweight and obesity (defined by a body mass index ≥25 kg/m2) has surged to concerning levels across many countries in the region, ranging from 25% to 82%, with a higher occurrence among women. Due to side effects of allopathic treatments and increase in nutrition knowledge people are more inclined to natural therapies. Subsequently, corn silk with nutraceutical properties may provide an effective alternative therapy to alleviate symptoms and decrease healthcare loss. Cornsilk, the often-overlooked byproduct of maize cultivation, is rich in bioactive compounds, including flavonoids, polysaccharides, and vitamins, cornsilk has shown promising effects in promoting health and wellness.

NCT ID: NCT06230861 Not yet recruiting - Clinical trials for Cardiometabolic Syndrome

Effects of Quercetin on Cardiometabolic Outcomes

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

NCT ID: NCT06226194 Recruiting - Metabolic Syndrome Clinical Trials

Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery

GENBASU
Start date: March 15, 2024
Phase:
Study type: Observational [Patient Registry]

Obesity is a complex chronic disease, in which both genetic and environmental factors are involved, that shows a great heterogeneity in the response to different weight loss programs. Identifying patients as responder or no responder to the different obesity treatment options is a concept of great interest, both due to the high prevalence of obesity and its high consumption of resources. More than 500,000 surgeries are performed every year around the world, of which approximately 30% will present unsatisfactory results. The general objective is to carry out a multi-omics approach for the discovery and validation of markers of weight response to bariatric surgery (BS) in a large sample of people with severe obesity (n=6,966 men and women who underwent sleeve gastrectomy or gastric bypass, including an additional external validation set). Thus, the investigators want to know the integrated contribution of several genomic markers (Genome Wide Association study, GWAs), new clinical and analytical variables (human exposome concept) and gender perspective to the prediction of response to the intervention at 12 month and its long-term longitudinal maintenance (3 years). The investigators intend, therefore, to provide new evidence to advance towards precision medicine. The investigators will focus our attention also on identifying those patients who, after being classified at the weight loss nadir as responders experienced weight regain.

NCT ID: NCT06216626 Active, not recruiting - Anxiety Clinical Trials

PRebiotic Intervention for Metabolic and MEntal Health (PRIME)

PRIME
Start date: June 19, 2023
Phase: N/A
Study type: Interventional

The purpose of the study is to determine whether a daily prebiotic fibre blend can reduce systemic inflammation, dyslipidemia, and self-report measures of mental health in individuals with metabolic syndrome. This study will help shape a larger randomised controlled study (RCT) powered to assess efficacy in a bigger cohort of patients. Primary outcome measures will explore the efficacy of a prebiotic fibre blend on systemic inflammation. Secondary and exploratory outcomes measures will explore the efficacy of the prebiotic blend on clinical biomarkers associated with cardiometabolic risk factors, microbiota features, and mental health. Using these data, we will also estimate in-year savings for the NHS in the metabolic syndrome population on a per participant basis.

NCT ID: NCT06214221 Active, not recruiting - Metabolic Syndrome Clinical Trials

Using Signos mHealth Platform in Adults for Weight Management

SWEET
Start date: January 2, 2024
Phase: N/A
Study type: Interventional

Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools that help participants in the pursuit of weight change goals. The investigators hypothesize that the use of CGM data and targeted coaching and nutrition education will assist with weight optimization goals in the general (non-diabetic) population using the Signos mHealth platform, with associated health benefits.

NCT ID: NCT06211868 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

RESET
Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

NCT ID: NCT06211465 Completed - Clinical trials for Cardiovascular Diseases

Cardiovascular And Metabolic Risk After Arthroplasty

CAMERA
Start date: March 1, 2014
Phase:
Study type: Observational

Osteoarthritis is a chronic joint disease that lacks curative therapy. Epidemiological studies show increase in the burden of disease. Total joint arthroplasty is one of the best treatment options for end-stage osteoarthritis. However, the specific effects of total joint arthroplasty on cardiovascular risk and metabolic profile are largely unknown. The aim of this project is to elucidate how hip and knee total joint arthroplasty impacts cardiovascular risk and metabolomic profile in comparison with general population. We hypothesize that arthroplasty decreases pain, systemic inflammation levels and increases functional status that all lead to decreased metabolic and cardiovascular risk.

NCT ID: NCT06210230 Completed - Metabolic Syndrome Clinical Trials

Double-blind and Placebo-controlled Study on Intervention Effect of Medium and Long Chain Fatty Acid Triglyceride on Glycolipid Homeostasis in Patients With Metabolic Syndrome and Mechanisms

Start date: May 22, 2023
Phase: N/A
Study type: Interventional

Double-blind and placebo-controlled study on intervention effect of medium and long chain fatty acid triglyceride on glycolipid homeostasis in patients with metabolic syndrome and mechanisms

NCT ID: NCT06193746 Completed - Metabolic Syndrome Clinical Trials

Laser Efficiency on Metabolic Parameters

Start date: April 10, 2023
Phase:
Study type: Observational

Non-invasive laser therapy is laser blood irradiation improves many metabolic parameters. So, this study aims to assess the impact of Non-invasive laser therapy on lipid metabolism and renal out comes